Angiodynamics reports fiscal year 2022 fourth quarter and full-year financial results; issues fiscal year 2023 guidance
Latham, n.y.--(business wire)--angiodynamics, inc. (nasdaq: ango), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options and improving quality of life for patients, today announced financial results for the fourth quarter and fiscal year 2022, which ended may 31, 2022. “our strong performance during the quarter, driven by our med tech portfolio, is a direct result of the continued hard work and commitment of our angiodynamics team,” commented jim clemmer, president and chief executive officer of angiodynamics, inc. “we delivered on the strategic objectives for fiscal year 2022 that we laid out a year ago during our investor and technology day while managing through a number of macro-related headwinds, including supply chain disruptions and ongoing inflationary pressures. during our fourth quarter, we reduced our backlog as our manufacturing capacity improved, exiting the quarter more than 40% above the lows we experienced in december. in addition, we launched two new alphavac products and initiated two important clinical trials -- our preserve study for the use of nanoknife in prostate cancer and our apex study for the use of alphavac f18 in the treatment of pulmonary embolism. we remain committed to balancing and prioritizing investments in our business and enhancing our growth platforms while managing through ongoing inflationary pressures and other macroeconomic challenges. i am excited about the product launches and clinical milestones we expect to achieve in fiscal year 2023, and i look forward to the team’s continued transformation of angiodynamics.” fourth quarter 2022 financial results net sales for the fourth quarter of fiscal year 2022 were $87.0 million, an increase of 13.2% compared to the prior-year quarter. foreign currency translation did not have a significant impact on the company's net sales in the quarter. med tech net sales were $22.6 million, a 40.0% increase from $16.2 million in the prior- year period, while med device net sales were $64.4 million, an increase of 6.1% compared to $60.7 million in the prior-year period. med tech includes the auryon peripheral atherectomy platform, the thrombectomy platform and the nanoknife irreversible electroporation platform. endovascular therapies (formerly vascular interventions and therapies) net sales were $45.1 million, an increase of 18.5%, compared to $38.1 million a year ago. growth was driven by auryon sales during the quarter of $9.6 million, continuing the sequential growth trend in the business as well as strength in the company’s thrombectomy portfolio as compared to the prior year. oncology net sales were $15.1 million, an increase of 5.8%, compared to $14.3 million in the prior-year period. the year-over-year growth was largely due to increased net sales of disposables of nanoknife and microwave. vascular access net sales were $26.7 million, an increase of 9.3%, compared to $24.5 million a year ago. u.s. net sales in the fourth quarter of fiscal 2022 were $73.7 million, an increase of 15.9% from $63.6 million a year ago. international net sales were $13.3 million, an increase of 0.4%, compared to $13.2 million a year ago. gross margin for the fourth quarter of fiscal 2022 was 53.4%, a decrease of 170 basis points compared to the fourth quarter of fiscal 2021, but up sequentially from 52.2% in the third quarter. during the quarter, gross margin was negatively impacted by macro forces including labor shortages and increased costs for labor, raw materials, and freight. the company recorded a net loss of $6.3 million, or a loss per share of $0.16, in the fourth quarter of fiscal 2022. this compares to a net loss of $19.5 million, or a loss per share of $0.51, a year ago. excluding the items shown in the non-gaap reconciliation table below, adjusted net income for the fourth quarter of fiscal 2022 was $0.3 million, and adjusted earnings per share was $0.01, compared to adjusted net loss in the prior-year period of $0.1 million and adjusted earnings per share of $0.00. adjusted ebitda in the fourth quarter of fiscal 2022, excluding the items shown in the reconciliation table below, was $6.2 million, compared to $4.5 million in the fourth quarter of fiscal 2021. in the fourth quarter of fiscal 2022, the company generated $8.6 million in operating cash, had capital expenditures of $1.0 million and additions to auryon placement and evaluation units of $2.7 million. at may 31, 2022, the company had $28.8 million in cash and cash equivalents compared to $23.9 million in cash and cash equivalents at february 28, 2022. the company had $25.0 million outstanding under its revolving credit facility at may 31, 2022 which was in line with february 28, 2022. full-year 2022 financial results for the twelve months ended may 31, 2022: net sales were $316.2 million, an increase of 8.7%, compared to $291.0 million for the same period a year ago. med tech net sales were $78.7 million, a 41.2% increase from the prior year period. med device net sales were $237.5 million, an increase of 0.9% from the prior year period. gross margin declined 150 basis points to 52.4% from 53.9% a year ago due to elevated labor, material, and freight costs, as well as auryon start-up costs. the company's net loss from continuing operations was $26.5 million, or a loss per share of $0.68, compared to a net loss of $31.5 million, or a loss of $0.82 per share, a year ago. excluding the items shown in the non-gaap reconciliation table below, adjusted net loss was $0.2 million, with adjusted earnings per share of $0.00, compared to adjusted net income and adjusted earnings per share of $1.9 million, or $0.05 per share, a year ago. adjusted net income and adjusted earnings per share in fiscal 2022 includes a $4.2 million, and $0.08 per share benefit, respectively, related to the reimbursement of certain expenses under the employee retention credit as part of the cares act. a similar reimbursement benefit of $1.9 million was included in the prior year period. adjusted ebitda, excluding the items shown in the reconciliation table below, was $20.9 million, compared to $19.5 million for the same period a year ago. fiscal year 2023 financial guidance the company expects its fiscal year 2023 net sales to be in the range of $342 to $348 million, gross margin to be approximately 52.5% to 54.5% and adjusted earnings per share in the range of $0.01 to $0.06 as it continues to invest in new product launches to drive future growth. conference call the company's management will host a conference call today at 8:00 a.m. et to discuss its fourth quarter and fiscal year 2022 results. to participate in the conference call, dial 1-877-407-0784 (domestic) or +1-201-689-8560 (international) and refer to the passcode 13730672. this conference call will also be webcast and can be accessed from the “investors” section of the angiodynamics website at www.angiodynamics.com. the webcast replay of the call will be available at the same site approximately one hour after the end of the call. a recording of the call will also be available from 11:00 a.m. et on tuesday, july 12, 2022, until 11:59 p.m. et on tuesday, july 19, 2022. to hear this recording, dial 1-844-512-2921 (domestic) or +1-412-317-6671 (international) and enter the passcode 13730672. use of non-gaap measures management uses non-gaap measures to establish operational goals and believes that non-gaap measures may assist investors in analyzing the underlying trends in angiodynamics' business over time. investors should consider these non-gaap measures in addition to, not as a substitute for or as superior to, financial reporting measures prepared in accordance with gaap. in this news release, angiodynamics has reported adjusted ebitda, adjusted net income and adjusted earnings per share. management uses these measures in its internal analysis and review of operational performance. management believes that these measures provide investors with useful information in comparing angiodynamics' performance over different periods. by using these non-gaap measures, management believes that investors get a better picture of the performance of angiodynamics' underlying business. management encourages investors to review angiodynamics' financial results prepared in accordance with gaap to understand angiodynamics' performance taking into account all relevant factors, including those that may only occur from time to time but have a material impact on angiodynamics' financial results. please see the tables that follow for a reconciliation of non-gaap measures to measures prepared in accordance with gaap. about angiodynamics, inc. angiodynamics is a leading, and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options and improving quality of life for patients. the company’s innovative technologies and devices are chosen by talented physicians in fast-growing healthcare markets to treat unmet patient needs. for more information, visit www.angiodynamics.com. safe harbor this release contains forward-looking statements within the meaning of the private securities litigation reform act of 1995. all statements regarding angiodynamics' expected future financial position, results of operations, cash flows, business strategy, budgets, projected costs, capital expenditures, products, competitive positions, growth opportunities, plans and objectives of management for future operations, as well as statements that include the words such as "expects," "reaffirms," "intends," "anticipates," "plans," "believes," "seeks," "estimates," “projects”, "optimistic," or variations of such words and similar expressions, are forward-looking statements. these forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties. investors are cautioned that actual events or results may differ materially from angiodynamics' expectations, expressed or implied. factors that may affect the actual results achieved by angiodynamics include, without limitation, the scale and scope of the covid-19 global pandemic, the ability of angiodynamics to develop its existing and new products, technological advances and patents attained by competitors, infringement of angiodynamics' technology or assertions that angiodynamics' technology infringes the technology of third parties, the ability of angiodynamics to effectively compete against competitors that have substantially greater resources, future actions by the fda or other regulatory agencies, domestic and foreign health care reforms and government regulations, results of pending or future clinical trials, overall economic conditions (including inflation, labor shortages and supply chain challenges including the cost and availability of raw materials), the results of on-going litigation, challenges with respect to third-party distributors or joint venture partners or collaborators, the results of sales efforts, the effects of product recalls and product liability claims, changes in key personnel, the ability of angiodynamics to execute on strategic initiatives, the effects of economic, credit and capital market conditions, general market conditions, market acceptance, foreign currency exchange rate fluctuations, the effects on pricing from group purchasing organizations and competition, the ability of angiodynamics to obtain regulatory clearances or approval of its products, or to integrate acquired businesses, as well as the risk factors listed from time to time in angiodynamics' sec filings, including but not limited to its annual report on form 10-k for the year ended may 31, 2021. angiodynamics does not assume any obligation to publicly update or revise any forward-looking statements for any reason. in the united states, the nanoknife system has received a 510(k) clearance by the food and drug administration for use in the surgical ablation of soft tissue and is similarly approved for commercialization in canada, the european union, and australia. the nanoknife system has not been cleared for the treatment or therapy of a specific disease or condition. angiodynamics, inc. and subsidiaries consolidated income statements (in thousands, except per share data) three months ended twelve months ended may 31, 2022 may 31, 2021 may 31, 2022 may 31, 2021 (unaudited) (unaudited) (audited) net sales $ 86,998 $ 76,842 $ 316,219 $ 291,010 cost of sales (exclusive of intangible amortization) 40,543 34,522 150,487 134,222 gross profit 46,455 42,320 165,732 156,788 % of net sales 53.4 % 55.1 % 52.4 % 53.9 % operating expenses research and development 7,866 9,104 30,739 36,390 sales and marketing 26,833 23,820 95,301 81,306 general and administrative 11,103 9,131 38,451 35,918 amortization of intangibles 4,853 4,298 19,458 18,136 change in fair value of contingent consideration 207 379 1,212 89 acquisition, restructuring and other items, net 1,990 17,175 9,042 20,232 total operating expenses 52,852 63,907 194,203 192,071 operating loss (6,397 ) (21,587 ) (28,471 ) (35,283 ) interest expense, net (185 ) (185 ) (688 ) (861 ) other income (expense), net (139 ) (167 ) (790 ) 92 total other expense, net (324 ) (352 ) (1,478 ) (769 ) loss before income tax benefit (6,721 ) (21,939 ) (29,949 ) (36,052 ) income tax benefit (455 ) (2,471 ) (3,402 ) (4,504 ) net loss $ (6,266 ) $ (19,468 ) $ (26,547 ) $ (31,548 ) loss per share basic $ (0.16 ) $ (0.51 ) $ (0.68 ) $ (0.82 ) diluted $ (0.16 ) $ (0.51 ) $ (0.68 ) $ (0.82 ) weighted average shares outstanding basic 39,160 38,525 39,009 38,342 diluted 39,160 38,525 39,009 38,342 angiodynamics, inc. and subsidiaries gaap to non-gaap reconciliation (in thousands, except per share data) reconciliation of net loss to non-gaap adjusted net income (loss): three months ended twelve months ended may 31, 2022 may 31, 2021 may 31, 2022 may 31, 2021 (unaudited) (unaudited) net loss $ (6,266 ) $ (19,468 ) $ (26,547 ) $ (31,548 ) amortization of intangibles 4,853 4,298 19,458 18,136 change in fair value of contingent consideration 207 379 1,212 89 acquisition, restructuring and other items, net (1) 1,990 17,175 9,042 20,232 tax effect of non-gaap items (2) (531 ) (2,451 ) (3,347 ) (5,057 ) adjusted net income (loss) $ 253 $ (67 ) $ (182 ) $ 1,852 reconciliation of diluted loss per share to non-gaap adjusted diluted earnings (loss) per share: three months ended twelve months ended may 31, 2022 may 31, 2021 may 31, 2022 may 31, 2021 (unaudited) (unaudited) diluted loss per share $ (0.16 ) $ (0.51 ) $ (0.68 ) $ (0.82 ) amortization of intangibles 0.12 0.11 0.50 0.47 change in fair value of contingent consideration 0.01 0.01 0.03 — acquisition, restructuring and other items, net (1) 0.05 0.45 0.24 0.53 tax effect of non-gaap items (2) (0.01 ) (0.06 ) (0.09 ) (0.13 ) adjusted diluted earnings (loss) per share $ 0.01 $ 0.00 $ 0.00 $ 0.05 adjusted diluted sharecount (3) 40,250 38,525 39,009 39,110 (1) includes costs related to merger and acquisition activities, restructuring, and unusual items, including asset impairments and write-offs, certain litigation, and other items. fiscal year 2021 results include a $14.0 million write-off of oartrac intangible assets. (2) adjustment to reflect the income tax provision on a non-gaap basis has been calculated assuming no valuation allowance on the company's u.s. deferred tax assets and an effective tax rate of 23% for the periods ended may 31, 2022 and may 31, 2021. (3) diluted shares may differ for non-gaap measures as compared to gaap due to a gaap loss. angiodynamics, inc. and subsidiaries gaap to non-gaap reconciliation (continued) (in thousands, except per share data) reconciliation of net loss to adjusted ebitda: three months ended twelve months ended may 31, 2022 may 31, 2021 may 31, 2022 may 31, 2021 (unaudited) (unaudited) net loss $ (6,266 ) $ (19,468 ) $ (26,547 ) $ (31,548 ) income tax benefit (455 ) (2,471 ) (3,402 ) (4,504 ) interest expense, net 185 185 688 861 depreciation and amortization 7,628 6,485 29,194 25,761 change in fair value of contingent consideration 207 379 1,212 89 stock based compensation 2,903 2,227 10,692 8,625 acquisition, restructuring and other items, net (1) 1,990 17,175 9,042 20,232 adjusted ebitda $ 6,192 $ 4,512 $ 20,879 $ 19,516 per diluted share: adjusted ebitda $ 0.15 $ 0.12 $ 0.54 $ 0.50 (1) includes costs related to merger and acquisition activities, restructuring, and unusual items, including asset impairments and write-offs, certain litigation, and other items. fiscal year 2021 results include a $14.0 million write-off of oartrac intangible assets. angiodynamics, inc. and subsidiaries net sales by product category and by geography (in thousands) three months ended twelve months ended may 31, 2022 may 31, 2021 % growth currency impact constant currency growth may 31, 2022 may 31, 2021 % growth currency impact constant currency growth (unaudited) (unaudited) net sales med tech $ 22,611 $ 16,150 40.0 % $ 78,717 $ 55,731 41.2 % med device 64,387 60,692 6.1 % 237,502 235,279 0.9 % $ 86,998 $ 76,842 13.2 % (0.4 )% 12.8 % $ 316,219 $ 291,010 8.7 % 0.0 % 8.7 % net sales by product category endovascular therapies $ 45,126 $ 38,071 18.5 % $ 160,925 $ 135,079 19.1 % vascular access 26,734 24,462 9.3 % 100,193 101,310 (1.1 )% oncology 15,138 14,309 5.8 % 55,101 54,621 0.9 % $ 86,998 $ 76,842 13.2 % (0.4 )% 12.8 % $ 316,219 $ 291,010 8.7 % 0.0 % 8.7 % net sales by geography united states $ 73,704 $ 63,597 15.9 % $ 265,963 $ 237,043 12.2 % international 13,294 13,245 0.4 % (2.5 )% (2.1 )% 50,256 53,967 (6.9 )% 0.2 % (6.7 )% $ 86,998 $ 76,842 13.2 % (0.4 )% 12.8 % $ 316,219 $ 291,010 8.7 % 0.0 % 8.7 % angiodynamics, inc. and subsidiaries consolidated balance sheets (in thousands) may 31, 2022 may 31, 2021 (unaudited) (audited) assets current assets: cash and cash equivalents $ 28,825 $ 48,161 accounts receivable, net 52,304 35,405 inventories 51,392 48,614 prepaid expenses and other 10,824 8,699 total current assets 143,345 140,879 property, plant and equipment, net 45,005 37,073 other assets 10,963 13,193 intangible assets, net 152,380 168,977 goodwill 201,058 201,316 total assets $ 552,751 $ 561,438 liabilities and stockholders' equity current liabilities: accounts payable $ 28,047 $ 19,630 accrued liabilities 34,842 35,459 current portion of contingent consideration 8,783 — other current liabilities 2,652 2,495 total current liabilities 74,324 57,584 long-term debt, net of current portion 25,000 20,000 deferred income taxes 16,037 19,955 contingent consideration, net of current portion 8,165 15,741 other long-term liabilities 4,736 8,701 total liabilities 128,262 121,981 stockholders' equity 424,489 439,457 total liabilities and stockholders' equity $ 552,751 $ 561,438 angiodynamics, inc. and subsidiaries consolidated statements of cash flows (in thousands) three months ended twelve months ended may 31, 2022 may 31, 2021 may 31, 2022 may 31, 2021 (unaudited) (unaudited) (audited) cash flows from operating activities: net loss $ (6,266 ) $ (19,468 ) $ (26,547 ) $ (31,548 ) adjustments to reconcile net loss to net cash provided by (used in) operating activities: depreciation and amortization 7,667 6,524 29,349 25,916 non-cash lease expense 617 596 2,439 2,456 stock based compensation 2,903 2,227 10,692 8,625 change in fair value of contingent consideration 207 379 1,212 89 deferred income tax provision (587 ) (2,618 ) (3,708 ) (4,805 ) change in accounts receivable allowances 184 176 118 207 asset impairments and disposals 146 14,038 391 14,228 other (66 ) 2 (93 ) (147 ) changes in operating assets and liabilities, net of acquisitions: accounts receivable (10,710 ) (2,339 ) (17,151 ) (4,162 ) inventories (3,384 ) 420 (2,796 ) 11,539 prepaid expenses and other 2,135 5,640 (5,012 ) (3,181 ) accounts payable, accrued and other liabilities 15,714 6,622 3,912 4,876 net cash provided by (used in) operating activities 8,560 12,199 (7,194 ) 24,093 cash flows from investing activities: additions to property, plant and equipment (1,039 ) (620 ) (4,297 ) (5,187 ) additions to placement and evaluation units (2,734 ) (8,524 ) (11,410 ) (8,524 ) acquisition of intangibles — — — — cash paid in acquisition — — (3,600 ) — net cash used in investing activities (3,773 ) (9,144 ) (19,307 ) (13,711 ) cash flows from financing activities: repayment of long-term debt — (10,000 ) — (20,000 ) proceeds from borrowings on long-term debt — — 5,000 — proceeds from exercise of stock options and employee stock purchase plan 329 555 2,683 3,014 net cash provided by (used in) financing activities 329 (9,445 ) 7,683 (16,986 ) effect of exchange rate changes on cash and cash equivalents (181 ) 82 (518 ) 330 increase (decrease) in cash and cash equivalents 4,935 (6,308 ) (19,336 ) (6,274 ) cash and cash equivalents at beginning of period 23,890 54,469 48,161 54,435 cash and cash equivalents at end of period $ 28,825 $ 48,161 $ 28,825 $ 48,161
